Effectiveness of BNT162b2 third dose against Omicron-associated severe disease

Researchers analyzed the effectiveness of the SARS-CoV-2 BNT162b2 third vaccine dose against SARS-CoV-2 Omicron-induced severe infection nearly seven months post-vaccination.